PROGEN – Making life science better. Together.
PROGEN was founded in 1983 by four scientists from Heidelberg, Germany, who joined forces to manufacture and supply high quality antibodies for biomedical research.
We help scientists worldwide drive biopharmaceutical and diagnostic progress to provide high-quality and reliable treatments for patients. Our mission is to make new therapies safe and affordable and to improve existing research processes.
The PROGEN team consists of bioscientists and adeno-associated virus (AAV) experts who collaborate with specialists around the world. Our products are essentials for research in
science and industry.
We are more than just a manufacturer of antibodies, AAV gene therapy tools, density gradient media, and phage display technologies. We strive to understand the needs of scientists to develop solutions to jointly address challenges in academic research, biotechnology and pharma.
As a subsidiary of the R-Biopharm Group, PROGEN’s antibodies developed through scientific collaborations are manufactured in Germany and highly validated. PROGEN’s quality management system has been certified to EN ISO 13485:2003 + AC:2007 standard.
Popular product ranges:
- Adeno-Associated Virus (AAV) – a unique range of adeno-associated virus (AAV) antibodies and quantification ELISAs for gene therapy research. Including AAV Titration ELISA kits and AAV ELISA controls for the quantitation of virions and assembled empty capsids of AAV1, AAV2, AAV3, AAV5, AAV6, AAV8 and AAV9.
- Phage Display – antibody hyperphage display technology for the generation of recombinant antibodies, proteins or peptides. Includes antibodies against M13, fd and F1 filamentous phages, Hyperphage M13, Library primer sets and expression vectors.